Literature DB >> 25944903

FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.

Zhichao Mei1, Dawei Zhang1, Bo Hu1, Jing Wang1, Xian Shen2, Wuhan Xiao3.   

Abstract

FBXO32 (MAFbx/Atrogin-1) is an E3 ubiquitin ligase that is markedly up-regulated in muscle atrophy. Although some data indicate that FBXO32 may play an important role in tumorigenesis, the molecular mechanism of FBXO32 in tumorigenesis has been poorly understood. Here, we present evidence that FBXO32 targets the oncogenic protein c-Myc for ubiquitination and degradation through the proteasome pathway. Phosphorylation of c-Myc at Thr-58 and Ser-62 is dispensable for FBXO32 to induce c-Myc degradation. Mutation of the lysine 326 in c-Myc reduces c-Myc ubiquitination and prevents the c-Myc degradation induced by FBXO32. Furthermore, overexpression of FBXO32 suppresses c-Myc activity and inhibits cell growth, but knockdown of FBXO32 enhances c-Myc activity and promotes cell growth. Finally, we show that FBXO32 is a direct downstream target of c-Myc, highlighting a negative feedback regulation loop between c-Myc and FBXO32. Thus, FBXO32 may function by targeting c-Myc. This work explains the function of FBXO32 and highlights its mechanisms in tumorigenesis.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  FBXO32; Myc (c-Myc); cell proliferation; muscle atrophy; oncogene; proteasomal degradation; ubiquitylation (ubiquitination)

Mesh:

Substances:

Year:  2015        PMID: 25944903      PMCID: PMC4481220          DOI: 10.1074/jbc.M115.645978

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Dynamics of the p53-Mdm2 feedback loop in individual cells.

Authors:  Galit Lahav; Nitzan Rosenfeld; Alex Sigal; Naama Geva-Zatorsky; Arnold J Levine; Michael B Elowitz; Uri Alon
Journal:  Nat Genet       Date:  2004-01-18       Impact factor: 38.330

2.  Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.

Authors:  Masayoshi Yada; Shigetsugu Hatakeyama; Takumi Kamura; Masaaki Nishiyama; Ryosuke Tsunematsu; Hiroyuki Imaki; Noriko Ishida; Fumihiko Okumura; Keiko Nakayama; Keiichi I Nakayama
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

3.  Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover.

Authors:  Nikita Popov; Christina Schülein; Laura A Jaenicke; Martin Eilers
Journal:  Nat Cell Biol       Date:  2010-09-19       Impact factor: 28.824

4.  p53 directly suppresses BNIP3 expression to protect against hypoxia-induced cell death.

Authors:  Xi Feng; Xing Liu; Wei Zhang; Wuhan Xiao
Journal:  EMBO J       Date:  2011-07-26       Impact factor: 11.598

5.  Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase.

Authors:  Lionel A Tintignac; Julie Lagirand; Sabrina Batonnet; Valentina Sirri; Marie Pierre Leibovitch; Serge A Leibovitch
Journal:  J Biol Chem       Date:  2004-11-05       Impact factor: 5.157

6.  SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.

Authors:  Gabriel Bretones; Juan C Acosta; Juan M Caraballo; Nuria Ferrándiz; M Teresa Gómez-Casares; Marta Albajar; Rosa Blanco; Paula Ruiz; Wen-Chun Hung; M Pilar Albero; Ignacio Perez-Roger; Javier León
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

7.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

Authors:  Marco Sandri; Claudia Sandri; Alex Gilbert; Carsten Skurk; Elisa Calabria; Anne Picard; Kenneth Walsh; Stefano Schiaffino; Stewart H Lecker; Alfred L Goldberg
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

8.  Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.

Authors:  Jian-Liang Chou; Her-Young Su; Lin-Yu Chen; Yu-Ping Liao; Corinna Hartman-Frey; Yi-Hui Lai; Hui-Wen Yang; Daniel E Deatherage; Chieh-Ti Kuo; Yi-Wen Huang; Pearlly S Yan; Shu-Huei Hsiao; Chien-Kuo Tai; Huey-Jen L Lin; Ramana V Davuluri; Tai-Kuang Chao; Kenneth P Nephew; Tim H-M Huang; Hung-Cheng Lai; Michael W-Y Chan
Journal:  Lab Invest       Date:  2010-01-11       Impact factor: 5.662

9.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.

Authors:  Trevor N Stitt; Doreen Drujan; Brian A Clarke; Frank Panaro; Yekatarina Timofeyva; William O Kline; Michael Gonzalez; George D Yancopoulos; David J Glass
Journal:  Mol Cell       Date:  2004-05-07       Impact factor: 17.970

10.  Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation.

Authors:  Ping Xie; Shubin Guo; Yongna Fan; Hua Zhang; Dongfeng Gu; Huihua Li
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

View more
  27 in total

1.  Deubiquitinating c-Myc: USP36 steps up in the nucleolus.

Authors:  Xiao-Xin Sun; Rosalie C Sears; Mu-Shui Dai
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.

Authors:  H Zhou; Y Liu; R Zhu; F Ding; Y Wan; Y Li; Z Liu
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

Review 3.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

4.  3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer.

Authors:  Chong Yang; Ping Fan; Shikai Zhu; Hongji Yang; Xin Jin; Heshui Wu
Journal:  Oncol Lett       Date:  2018-03-28       Impact factor: 2.967

5.  SPSB3 targets SNAIL for degradation in GSK-3β phosphorylation-dependent manner and regulates metastasis.

Authors:  Y Liu; H Zhou; R Zhu; F Ding; Y Li; X Cao; Z Liu
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

6.  Selective Translation of Cell Fate Regulators Mediates Tolerance to Broad Oncogenic Stress.

Authors:  Elise Y Cai; Megan N Kufeld; Samantha Schuster; Sonali Arora; Madeline Larkin; Alexandre A Germanos; Andrew C Hsieh; Slobodan Beronja
Journal:  Cell Stem Cell       Date:  2020-06-08       Impact factor: 24.633

7.  miR-19a-3p Functions as an Oncogene by Regulating FBXO32 Expression in Multiple Myeloma.

Authors:  Ying Li; Song Gao; Wenjing Xue; Yanna Ma; Yuesheng Meng; Dawei Zhang
Journal:  Balkan Med J       Date:  2021-01       Impact factor: 2.021

8.  Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.

Authors:  Lei Zhu; Zhen Chen; Hongjing Zang; Songqing Fan; Jiajia Gu; Guojing Zhang; Kevin D-Y Sun; Qiming Wang; Yong He; Taofeek K Owonikoko; Suresh S Ramalingam; Shi-Yong Sun
Journal:  Cancer Res       Date:  2021-07-21       Impact factor: 12.701

Review 9.  The Role of GSK-3β in the Regulation of Protein Turnover, Myosin Phenotype, and Oxidative Capacity in Skeletal Muscle under Disuse Conditions.

Authors:  Timur M Mirzoev; Kristina A Sharlo; Boris S Shenkman
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

Review 10.  Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy.

Authors:  Xiao-Xin Sun; Yanping Li; Rosalie C Sears; Mu-Shui Dai
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.